Skip header and navigation

Refine By

132 records – page 1 of 14.

A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.

https://arctichealth.org/en/permalink/ahliterature56626
Source
Scand J Infect Dis. 2002;34(8):610-4
Publication Type
Article
Date
2002
Author
K. Levie
I. Gjorup
P. Skinhøj
M. Stoffel
Source
Scand J Infect Dis. 2002;34(8):610-4
Date
2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Belgium
Comparative Study
Denmark
Dose-Response Relationship, Drug
Female
Hepatitis B - prevention & control
Hepatitis B Antibodies - analysis
Hepatitis B Surface Antigens - analysis
Hepatitis B vaccines - administration & dosage
Humans
Immunity - physiology
Immunization - methods
Immunization Schedule
Male
Reference Values
Research Support, Non-U.S. Gov't
Sensitivity and specificity
Single-Blind Method
Vaccines, Synthetic - administration & dosage
Abstract
An open-label randomized study was undertaken to compare a 2-dose regimen (Months 0 and 6) of hepatitis B surface antigen (HBsAg) vaccine formulated with a novel adjuvant (HBsAg/AS04) with a standard 3-dose regimen (Months 0, 1 and 6) of licensed recombinant HBsAg vaccine in terms of immunogenicity and reactogenicity when administered to healthy subjects aged between 15 and 40 y. At 1 and 6 months after the full vaccination course there was a 100% seroprotection rate (anti-HBs > or = 10 mIU/ml) with the HBsAg/AS04 vaccine, compared with a 99% response rate with the licensed vaccine. The corresponding geometric mean titres were significantly higher for the novel vaccine compared to the standard vaccine: 15,468 and 2,745 mIU/ml at Months 7 and 12 vs. 6,274 and 1,883 mIU/ml, respectively. There was a higher prevalence of local symptoms with the adjuvant vaccine (90% of doses) than with the standard vaccine (48% of doses). However, these symptoms (pain, swelling and redness) were predominantly of mild-to-moderate intensity and resolved rapidly without treatment. A 2-dose regimen of the new HBsAg/AS04 adjuvant vaccine therefore compared favourably to the standard regimen in healthy young adults. It is anticipated that the simplified vaccination schedule may improve compliance and reduce costs.
PubMed ID
12238579 View in PubMed
Less detail

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.

https://arctichealth.org/en/permalink/ahliterature5719
Source
Journal of Infectious Diseases. 1985 Apr;151(4):599-603
Publication Type
Article
Date
Apr-1985
Author
B J McMahon
W L Alward
D B Hall
W L Heyward
T R Bender
D P Francis
J E Maynard
Source
Journal of Infectious Diseases. 1985 Apr;151(4):599-603
Date
Apr-1985
Language
English
Geographic Location
U.S.
Publication Type
Article
Physical Holding
Alaska Medical Library
Keywords
Acute Disease
Adolescent
Adult
Age Factors
Alaska
Carrier State - epidemiology
Child
Child, Preschool
Female
HBV
Hepatitis B - diagnosis - epidemiology
Hepatitis B Surface Antigens - analysis
Humans
Infant
Inuits
Male
Middle Aged
Prospective Studies
Risk
Sex Factors
Vaccine
Abstract
Yupik Eskimos of southwestern Alaska have the highest known prevalence of hepatitis B virus infection of any general population in the United States. Prospective serological surveys of 1,280 seronegative Yupik Eskimos, performed between 1971 and 1976, identified 189 (14.8%) who developed serological evidence of hepatitis B virus infection. Twenty-six (13.8%) developed clinical hepatitis during the interval when seroconversion occurred. The proportion of patients with clinically apparent hepatitis increased with age (P less than .01), ranging from 9.5% of infections in patients who were four years of age or less to 33.3% of infections in patients who were 30 years of age or older. Twenty-five (13.3%) of the 188 individuals who were studied became chronic carriers of hepatitis B surface antigen. The risk of becoming a carrier was inversely related to the age of the patient at the time of infection (P = .02). Among patients who were four years of age or less when infected, 28.8% became chronic carriers of hepatitis B, as compared with 7.7% of those who were 30 years of age or older.
Notes
From: Fortuine, Robert et al. 1993. The Health of the Inuit of North America: A Bibliography from the Earliest Times through 1990. University of Alaska Anchorage. Citation number 1937.
PubMed ID
3973412 View in PubMed
Less detail

Antibodies to hepatitic C virus and chronic liver disease among Finnish patients with haemophilia.

https://arctichealth.org/en/permalink/ahliterature227976
Source
Ann Med. 1990 Dec;22(6):393-6
Publication Type
Article
Date
Dec-1990
Author
F. Ebeling
V. Rasi
R. Naukkarinen
J. Leikola
Author Affiliation
Finnish Red Cross Blood Transfusion Service, Helsinki, Finland.
Source
Ann Med. 1990 Dec;22(6):393-6
Date
Dec-1990
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Alanine Transaminase - analysis
Antibodies, Viral - analysis
Child
Child, Preschool
Chronic Disease
Factor VIII - administration & dosage - therapeutic use
Female
Finland
Hemophilia A - complications - drug therapy - enzymology
Hepacivirus - immunology
Hepatitis B - complications - enzymology
Hepatitis B Core Antigens - analysis
Hepatitis B Surface Antigens - analysis
Hepatitis C - complications - enzymology
Humans
Infant
Male
Middle Aged
Abstract
Antibodies to hepatitis C virus, hepatitis B serology and liver enzymes were examined in 137 Finnish haemophiliac patients to detect signs of chronic viral hepatitis and its possible aetiological associations. The prevalence of raised alanine aminotransferase values was 37%. These were significantly associated with hepatitis C seropositivity but not with hepatitis B antibodies, severity of haemophilia or the type of clotting factor used in replacement therapy. The prevalence of hepatitis C seropositivity was 50%; it was significantly associated with severe haemophilia and with the use of large pool concentrates. The hepatitis C virus seems to be the major cause of chronic liver disease transmitted by clotting factors also in Finland, despite a somewhat lower seroprevalence than described elsewhere so far.
PubMed ID
1963789 View in PubMed
Less detail

Antibody to hepatitis D virus (delta agent) in selected Manitoba residents, 1974-1986.

https://arctichealth.org/en/permalink/ahliterature233014
Source
Clin Invest Med. 1988 Jun;11(3):209-12
Publication Type
Article
Date
Jun-1988
Author
C. Hannan
L. Sekla
B. Schacter
W. Stackiw
Author Affiliation
Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada.
Source
Clin Invest Med. 1988 Jun;11(3):209-12
Date
Jun-1988
Language
English
Publication Type
Article
Keywords
Carrier state
Hepatitis A - immunology
Hepatitis Antibodies - analysis
Hepatitis B - immunology
Hepatitis B Surface Antigens - analysis
Hepatitis C - immunology
Hepatitis Delta Virus - immunology
Humans
Manitoba
Reference Values
Abstract
The prevalence of antibody to Hepatitis D Virus (HDV) was determined in serum samples collected from 174 Manitoba residents between 1974 and 1986. Anti-delta was detected in five of 123 HBV-infected individuals for an overall prevalence of 4.1%. Three of 54 (5.5%) persons who were sampled in the period 1974-77 were anti-delta positive, as were two of 69 (2.9%) sampled between 1982 and 1986 (p greater than 0.05). Four of 31 (12.9%) acute hepatitis B patients, and one of 92 (1.1%) chronic HBsAg carriers were anti-delta positive. Three of four intravenous drug abusers were anti-delta positive, as compared to two of 69 who denied drug abuse (p less than 0.0005). In three of the four patients with acute delta hepatitis, anti-delta was detectable in convalescent serum only; all four patients made a complete clinical recovery. A possible false-positive reaction for anti-delta was observed in the serum of one of 51 HBsAg negative controls, a patient with acute hepatitis A who was negative for all hepatitis B markers. These results indicate that HDV has been present in Manitoba since at least 1974, though at a relatively low level, and that infection is strongly associated with intravenous drug abuse. Reliable detection of anti-delta in patients with acute delta hepatitis requires the testing of serial serum specimens.
PubMed ID
3135966 View in PubMed
Less detail

[Australia (HB) antigen carrier state in donors]

https://arctichealth.org/en/permalink/ahliterature57063
Source
Probl Gematol Pereliv Krovi. 1977 Dec;22(12):40-1
Publication Type
Article
Date
Dec-1977
Source
CMAJ. 1989 Aug 1;141(3):227-8
Publication Type
Article
Date
Aug-1-1989
Source
CMAJ. 1989 Aug 1;141(3):227-8
Date
Aug-1-1989
Language
English
Publication Type
Article
Keywords
Aged
Bacterial Vaccines - therapeutic use
Canada
Female
Hepatitis B Surface Antigens - analysis
Humans
Immunization
Mass Screening
Pregnancy
Streptococcus pneumoniae - immunology
Notes
Cites: Am J Epidemiol. 1987 Sep;126(3):484-913618580
Cites: Obstet Gynecol. 1987 May;69(5):701-43574797
Cites: Chest. 1987 Mar;91(3):436-433816320
Cites: Soc Sci Med. 1985;20(6):601-73923626
Cites: Ann Intern Med. 1986 Jan;104(1):1-63940476
Cites: Can Dis Wkly Rep. 1988 Aug 6;14(31):137-403242888
Cites: Arch Intern Med. 1986 Jun;146(6):1207-83521520
Cites: JAMA. 1988 Jan 15;259(3):365-92961895
Cites: Ann Intern Med. 1987 Sep;107(3):335-73039886
Cites: CMAJ. 1986 Apr 15;134(8):897-9013955483
Cites: Rev Epidemiol Sante Publique. 1985;33(6):437-443914014
Cites: Am J Dis Child. 1986 May;140(5):428-323962935
Cites: Ann Intern Med. 1988 May;108(5):653-73358567
PubMed ID
2752349 View in PubMed
Less detail

Changing prevalence of hepatitis B virus genotypes in Iceland.

https://arctichealth.org/en/permalink/ahliterature56563
Source
J Med Virol. 2005 Dec;77(4):481-5
Publication Type
Article
Date
Dec-2005
Author
Thora B Björnsdottir
Barbara Stanzeit
Matti Sällberg
Arthur Löve
Catharina Hultgren
Author Affiliation
Division of Clinical Virology F68, Karolinska Institute, Institute of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden.
Source
J Med Virol. 2005 Dec;77(4):481-5
Date
Dec-2005
Language
English
Publication Type
Article
Keywords
DNA, Viral - blood - genetics
Epidemiology, Molecular
Genotype
Hepatitis B - epidemiology - virology
Hepatitis B Surface Antigens - analysis
Hepatitis B virus - drug effects - genetics
Humans
Iceland - epidemiology
Prevalence
Research Support, Non-U.S. Gov't
Abstract
At present eight hepatitis B virus (HBV) genotypes have been characterized: A to H. The most common genotype in Northern Europe is genotype A. So far there is no record of the specific HBV genotype distribution in Iceland. Iceland has a small population whose homogeneity has changed due to increasing migration during the past decades. The distribution of HBV genotypes in Iceland was analyzed using sera from 170 Icelandic patients. The samples were obtained before 1989, during an HBV epidemic among intravenous drug users in 1989 to 1992 and after 1994. A fragment of the HBV S-gene was amplified, sequenced and subjected to phylogenetic analysis. Among samples derived before 1989 genotypes A, C, and D were found. Most of the samples diagnosed during the epidemic belonged to genotype D and a smaller portion to genotype A. This suggests that the epidemic was most likely caused either by an endogenous HBV strain or by a strain imported from Europe or the USA. Among samples obtained after 1994, genotypes A to E and G were found, but the majority were of genotypes A, C, and D. This is consistent with an increase in migration and immigration from regions in Asia and Africa during the past 10 years. Thus, the changing prevalence of HBV genotypes in a small isolated community such as Iceland reflects the influence of migration and increasing contacts with regions outside the Western World.
PubMed ID
16254980 View in PubMed
Less detail

[Characteristics of the epidemic process manifested as chronic viral hepatitis].

https://arctichealth.org/en/permalink/ahliterature233449
Source
Zh Mikrobiol Epidemiol Immunobiol. 1988 Mar;(3):44-8
Publication Type
Article
Date
Mar-1988
Author
V V Nechaev
L I Shliakhtenko
S L Mukomolov
L N Kryga
V A Shargorodskaia
Source
Zh Mikrobiol Epidemiol Immunobiol. 1988 Mar;(3):44-8
Date
Mar-1988
Language
Russian
Publication Type
Article
Keywords
Disease Outbreaks
Hepatitis B
Hepatitis B Surface Antigens - analysis
Hepatitis C
Hepatitis, Chronic - epidemiology - mortality
Humans
Russia
Sex Factors
Urban Population
Abstract
The incidence rates of chronic viral hepatitis in Leningrad over the period of 1962-1984 were studied. The tendency towards a rise in total morbidity because of increased incidence of chronic hepatitis B was shown to appear in recent years. This increase in morbidity was mainly due to its rise among adult males and children, which led to the shift of morbidity to younger age groups. The seasonal rises of morbidity in winter and spring were found to be characteristic of viral hepatitis.
PubMed ID
2968737 View in PubMed
Less detail

132 records – page 1 of 14.